Skip to main content

Bivalirudin, thrombin and platelets: clinical implications and future directions.

Publication ,  Journal Article
Becker, R; Butenas, S; Carr, M; Jaffer, F; Kleiman, NS; Marmur, JD; Schneider, DJ; Spiess, BD; Steinhubl, SR; Weitz, JI
Published in: The Journal of invasive cardiology
2003

Our current understanding of hemostasis and the roles of coagulation and platelets has evolved in recent years from the old "coagulation cascade" and "platelet pathway" models to an inter-related, cell-based model that more accurately represents in-vivo processes and better reflects clinical observations. The new model makes it apparent that thrombin is a key effector and modulator of hemostasis, and that activation of coagulation and platelets cannot be viewed as separate processes. Thrombin is a potent platelet agonist, and recent data indicate that thrombin may be the most critical activator of tissue-factor-induced thrombosis. Minute quantities of thrombin generated at the site of plaque disruption or arterial injury activates platelets and amplifies its own production, resulting in an explosive burst of thrombin production after clot formation. Thrombin-induced activation of platelets and other cells may contribute to inflammatory processes that are increasingly recognized as playing an important role in acute coronary syndromes (ACS) and coronary interventions. Along with a clearer understanding of the biology of thrombosis and hemostasis, better methods for studying the mechanisms of coagulation and platelet activation and the interaction of these processes in vivo have provided a new understanding of the method by which antithrombotic agents work. The physiological basis of thrombosis and hemostasis has important implications for treatment strategies in ACS, and for outcomes of percutaneous coronary interventions (PCI). With this increased understanding, the limitations of heparin and the advantages of the direct thrombin inhibitor bivalirudin (Angiomax, The Medicines Company) become apparent--providing a mechanistic rationale for the clinical benefit recently demonstrated in the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) PCI trial.

Duke Scholars

Published In

The Journal of invasive cardiology

ISSN

1042-3931

Publication Date

2003

Volume

Suppl

Start / End Page

2 / 15

Related Subject Headings

  • Cardiovascular System & Hematology
  • 1102 Cardiorespiratory Medicine and Haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Becker, R., Butenas, S., Carr, M., Jaffer, F., Kleiman, N. S., Marmur, J. D., … Weitz, J. I. (2003). Bivalirudin, thrombin and platelets: clinical implications and future directions. The Journal of Invasive Cardiology, Suppl, 2–15.
Becker, R., S. Butenas, M. Carr, F. Jaffer, N. S. Kleiman, J. D. Marmur, D. J. Schneider, B. D. Spiess, S. R. Steinhubl, and J. I. Weitz. “Bivalirudin, thrombin and platelets: clinical implications and future directions.The Journal of Invasive Cardiology Suppl (2003): 2–15.
Becker R, Butenas S, Carr M, Jaffer F, Kleiman NS, Marmur JD, et al. Bivalirudin, thrombin and platelets: clinical implications and future directions. The Journal of invasive cardiology. 2003;Suppl:2–15.
Becker, R., et al. “Bivalirudin, thrombin and platelets: clinical implications and future directions.The Journal of Invasive Cardiology, vol. Suppl, 2003, pp. 2–15.
Becker R, Butenas S, Carr M, Jaffer F, Kleiman NS, Marmur JD, Schneider DJ, Spiess BD, Steinhubl SR, Weitz JI. Bivalirudin, thrombin and platelets: clinical implications and future directions. The Journal of invasive cardiology. 2003;Suppl:2–15.

Published In

The Journal of invasive cardiology

ISSN

1042-3931

Publication Date

2003

Volume

Suppl

Start / End Page

2 / 15

Related Subject Headings

  • Cardiovascular System & Hematology
  • 1102 Cardiorespiratory Medicine and Haematology